The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity
mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universitat Pompeu Fabra |
| Repositorio: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/52261 |
| Acceso en línea: | http://hdl.handle.net/10230/52261 http://dx.doi.org/10.3389/fimmu.2021.737083 |
| Access Level: | acceso abierto |
| Palabra clave: | COVID-19 (Malaltia) Vacunació Immunitat |
| id |
ES_232ee622b8cec100e89afb867fa09810 |
|---|---|
| oai_identifier_str |
oai:repositori.upf.edu:10230/52261 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunityTejedor Vaquero, Sonia, 1988-Campos Mata, Leire de, 1991-Ramada Rodilla, José María, 1961-Díaz, PilarNavarro-Barriuso, JuanRibas-Llauradó, ClaraRodrigo Melero, NataliaCarolis, CarloCerutti, Andrea, 1965-Gimeno Martínez, RamónMagri, Giuliana, 1978-COVID-19 (Malaltia)VacunacióImmunitatmRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen.This study was supported by the COVID-19 call grant from Generalitat de Catalunya, Department of Health (to GM), grant Miguel Servet research program (to GM) and by National Health Institute Carlos III (ISCIII) through the project COV20_00508 grant (Co-funded by European Regional Development Fund/European Social Fund “a way to make Europe) (to RG)Frontiers Media202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/52261http://dx.doi.org/10.3389/fimmu.2021.737083reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésFrontiers in Immunology. 2021;12:737083.© 2021 Sonia Tejedor Vaquero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these termshttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/522612026-06-12T07:21:37Z |
| dc.title.none.fl_str_mv |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| title |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| spellingShingle |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity Tejedor Vaquero, Sonia, 1988- COVID-19 (Malaltia) Vacunació Immunitat |
| title_short |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| title_full |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| title_fullStr |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| title_full_unstemmed |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| title_sort |
The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity |
| dc.creator.none.fl_str_mv |
Tejedor Vaquero, Sonia, 1988- Campos Mata, Leire de, 1991- Ramada Rodilla, José María, 1961- Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llauradó, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea, 1965- Gimeno Martínez, Ramón Magri, Giuliana, 1978- |
| author |
Tejedor Vaquero, Sonia, 1988- |
| author_facet |
Tejedor Vaquero, Sonia, 1988- Campos Mata, Leire de, 1991- Ramada Rodilla, José María, 1961- Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llauradó, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea, 1965- Gimeno Martínez, Ramón Magri, Giuliana, 1978- |
| author_role |
author |
| author2 |
Campos Mata, Leire de, 1991- Ramada Rodilla, José María, 1961- Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llauradó, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea, 1965- Gimeno Martínez, Ramón Magri, Giuliana, 1978- |
| author2_role |
author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
COVID-19 (Malaltia) Vacunació Immunitat |
| topic |
COVID-19 (Malaltia) Vacunació Immunitat |
| description |
mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 2022 2022 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10230/52261 http://dx.doi.org/10.3389/fimmu.2021.737083 |
| url |
http://hdl.handle.net/10230/52261 http://dx.doi.org/10.3389/fimmu.2021.737083 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Frontiers in Immunology. 2021;12:737083. |
| dc.rights.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Frontiers Media |
| publisher.none.fl_str_mv |
Frontiers Media |
| dc.source.none.fl_str_mv |
reponame:Repositorio Digital de la UPF instname:Universitat Pompeu Fabra |
| instname_str |
Universitat Pompeu Fabra |
| reponame_str |
Repositorio Digital de la UPF |
| collection |
Repositorio Digital de la UPF |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869404626008145920 |
| score |
15,812429 |